Biogen, Eisai’s Alzheimer’s drug aducanumab makes history with US approval
First new treatment approved for Alzheimer’s disease in over a decade
Read More
Tag: aducanumab
Another mid-late stage Alzheimer’s flop, this time for Lilly
Earlier this month, Roche also announced a gantenerumab Alzheimer’s failure, and last year Biogen and Eisai stopped two global Phase III trials of aducanumab.
Read More
Eisai, Biogen move Alzheimer’s treatment into Phase III
Eisai and Biogen’s BAN2401 is to be put into Phase III trial for patients with early Alzheimer’s disease.
Read More
Alzheimer’s trial discontinued due to inefficiency
Two global Phase III trials of the Alzheimer’s drug aducanumab have been discontinued, after the drug failed to hit efficacy targets.
Read More
Biogen takes up option to co-develop Eisai AD drug
Biogen and Eisai have expanded their existing collaboration agreement to develop and commercialise investigational therapies for Alzheimer’s Disease.
Read More
- UKHSA and ICL confirm variant which plays key role in global surge of Strep A infections
- Study reveals heart failure device could monitor patients and prevent hospitalisation
- MIT’s new MRI brain light-detecting technique could support brain cell studies
- PharmaTimes MSEA and NIEA awards are open for entry
- BBSRC invests £48m in Babraham Institute to advance lifelong health research
